Business
RYALTRIS®, a new combination prescription nasal spray for moderate to severe seasonal allergic rhinitis (SAR), now available across Canada
RYALTRIS®, a new combination prescription nasal spray for moderate to severe seasonal allerg...
About this update from Bausch Health Companies Inc.
[{"type":"text","content":"\n \n \n \n RYALTRIS®, a new combination prescription nasal spray for moderate to severe seasonal allergic rhinitis (SAR), now available across Canada\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nPADDING-RIGHT:0.17em; PADDING-LEFT:0.17em; VERTICAL-ALIGN: BOTTOM; BORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; BORDER-BOTTOM:black 0pt; BORDER-LEFT:black 0pt\n}\n.prnml4{\nMARGIN-TOP:0em; MARGIN-RIGHT:0em; MARGIN-BOTTOM:0em; MARGIN-LEFT:0.33em !IMPORTANT\n}\n.prnbcc{\nBORDER-COLLAPSE: COLLAPSE\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n New treatment from Bausch Health,\n \n Canada\n \n indicated to treat seasonal allergy and associated ocular symptoms in adults, adolescents and children 6 years and older\n \n \n \n \n \n LAVAL, QC\n \n \n ,\n \n \n May 3, 2023\n \n \n /CNW/ - Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC) is pleased to announce the availability across\n \n Canada\n \n of its new prescription treatment RYALTRIS\n \n ®\n \n (olopatadine hydrochloride and mometasone furoate nasal spray).\n \n \n \n \n \n \n \n \n \n RYALTRIS has been approved by Health Canada for the symptomatic treatment of moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptoms in adults, adolescents, and children aged 6 years and older.\n \n 1\n \n \n \n \"Bausch Health is very pleased that we are now able to make RYALTRIS available to Canadians, providing an innovative new combination nasal spray treatment for SAR, which impacts the lives of the over 9 million Canadians who suffer from SAR or seasonal allergies often referred to as hay fever,\n \n 2\n \n \" said\n \n Cees Heiman\n \n , Senior Vice-President,\n \n Europe\n \n and\n \n Canada\n \n , Bausch Health. \"The launch of this new therapy adds to our broad portfolio of treatments that further establishes Bausch Health as a trusted partner in the healthcare of Canadians.\"\n \n \n \"Allergic rhinitis is a common disorder that often doesn't respond adequately to usual treatments\" said Dr. Paul Keith, Professor, Division of Clinical Immunology and Allergy, Department of Me...